Workflow
CRDMO业务模式服务
icon
Search documents
CXO一哥药明康德上半年业绩出炉,净利润同比翻倍至86亿
Core Insights - WuXi AppTec reported significant growth in both revenue and profit for the first half of 2025, with revenue reaching 20.799 billion yuan, a year-on-year increase of 20.64%, and net profit attributable to shareholders soaring to 8.561 billion yuan, up 101.92% [1][2] Group 1: Financial Performance - In Q2 2025, the company achieved revenue of 11.14 billion yuan, marking a 20.4% year-on-year growth and surpassing the 10 billion yuan mark for the first time in this quarter [1][2] - The company’s investment income from the sale of shares in Wu Xi XDC Cayman Inc. amounted to approximately 3.669 billion yuan, representing a staggering year-on-year increase of about 163 times [2] - Historical revenue and profit data from 2020 to 2025 shows a consistent upward trend, with revenue increasing from 10.54 billion yuan in H1 2020 to 20.80 billion yuan in H1 2025, and net profit rising from 2.675 billion yuan to 8.561 billion yuan in the same period [2] Group 2: Business Structure and Market Performance - The chemical business, as the core segment, generated revenue of 16.3 billion yuan, reflecting a 33.5% year-on-year increase and accounting for 78% of total revenue [3] - The gross profit of the chemical business increased by 50.33%, with the gross margin rising to 49.07% [3] - Revenue from U.S. clients grew by 38.4% year-on-year, indicating a steady expansion of the company's global market presence [3] Group 3: Shareholder Returns - The company announced an interim dividend of 3.5 yuan per 10 shares, totaling approximately 1 billion yuan [3]